Stifel Starts Iveric Bio (ISEE) at Buy

Iveric bio (ISEE): APLS Data As Good As Possible for Iveric, Buy Here - Analyst

September 10, 2021 8:30 AM EDT

Late Thursday, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) reported top-line results from the Phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

OAKS study met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052), respectively, compared to pooled sham at 12 months

DERBY did not meet the primary endpoint of GA lesion growth,... More

Iveric Bio (ISEE) PT Raised to $21 at Wedbush

September 10, 2021 7:41 AM EDT

Wedbush analyst David Nierengarten raised the price target on Iveric Bio (NASDAQ: ISEE) to $21.00 (from $16.00) while maintaining an Outperform rating.

"In our opinion the Phase 3 results announced by APLS (Neutral, Laura Chico) represent a best-case scenario for ISEE shares," the analyst commented.

... More

Iveric Bio (ISEE) PT Raised to $25 at Cowen; APLS Data Disclosure 'As Good As Possible for Iveric'

September 10, 2021 6:48 AM EDT

Cowen analyst Ken Cacciatore raised the price target on Iveric Bio (NASDAQ: ISEE) to $25.00 (from $15.00) while maintaining an Outperform rating, saying the data from competitor APLS is as good as possible for the company.

The analyst commented, "The APLS results could not... More

After-Hours Stock Movers 09/09: (ISEE) (AFRM) (KPLT) Higher; (APLS) (COOK) (ZUMZ) Lower (more...)

September 9, 2021 5:52 PM EDT

After-Hours Stock Movers:

IVERIC bio (NASDAQ: ISEE) 41.4% HIGHER; gains following data from Apellis

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) 30.8% LOWER; reported top-line results from the Phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052), respectively,... More

UPDATE: IVERIC bio (ISEE) Gains Following Results From Apellis Pharmaceuticals (APLS)

September 9, 2021 4:14 PM EDT

(Updated - September 9, 2021 4:22 PM EDT)

IVERIC bio (NASDAQ: ISEE) Strength Post-Market Said Tied to Results from Apellis Pharmaceuticals (NASDAQ: APLS)

Shares Up 17%

Update:

Shares Are Now Up 22%Catalyst Biosciences (NASDAQ: CBIO) Also Gained, up 15%... More